Breztri Vs Trelegy: Battle Of The Breath-enhancing Titans

Let’s have a look at the differences of Breztri Vs Trelegy. Though both manage COPD, Breztri combines budesonide, glycopyrronium, and formoterol, targeting multiple aspects of COPD, while Trelegy contains fluticasone, umeclidinium, and vilanterol, offering a different triple therapy approach.

the realm of respiratory health, advancements in medication have significantly improved the lives of those living with chronic obstructive pulmonary disease (COPD). Two prominent contenders in this field are Breztri and Trelegy. These medications aim to enhance patients’ quality of life by managing COPD symptoms effectively. In this article, we will delve into a detailed comparison of Breztri and Trelegy, exploring their mechanisms, benefits, side effects, dosages, cost, real-life experiences, clinical studies, and more.

Understanding COPD and its Management

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that affects millions worldwide. It leads to breathing difficulties, reduced lung function, and a lower quality of life. COPD management involves a multifaceted approach, combining lifestyle changes, pulmonary rehabilitation, and medical interventions. Medications play a crucial role in alleviating symptoms and slowing disease progression.

Introduction to Breztri

Breztri, also known by its generic name as budesonide/glycopyrrolate/formoterol fumarate, is a triple combination inhaler. Its unique formulation combines three active ingredients, each addressing different aspects of COPD. Budesonide, a corticosteroid, reduces airway inflammation, while glycopyrrolate and formoterol fumarate act as long-acting bronchodilators. This combination allows for improved lung function and better symptom control.

Introduction to Trelegy

Trelegy, a triple therapy inhaler, contains three active components: fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that reduces inflammation, umeclidinium is an anticholinergic that helps open airways, and vilanterol is a long-acting beta-agonist that relaxes airway muscles. Trelegy’s three-pronged approach aims to provide comprehensive COPD management.

Breztri Vs Trelegy: Mechanism of Action

Breztri and Trelegy target key factors contributing to COPD symptoms. Breztri’s combination of budesonide, glycopyrrolate, and formoterol fumarate addresses inflammation and bronchodilation simultaneously. Trelegy’s trio of fluticasone furoate, umeclidinium, and vilanterol work synergistically to reduce inflammation, prevent airway constriction, and improve airflow. These medications not only provide relief but also contribute to long-term lung health.

Breztri Vs Trelegy: Benefits


Breztri offers several benefits for COPD patients. Its triple combination of active ingredients provides comprehensive treatment, making it suitable for a broad range of patients. By targeting multiple aspects of the disease, Breztri can lead to improved lung function, reduced exacerbations, and enhanced quality of life. Additionally, its single inhaler convenience promotes adherence to the treatment regimen.


Trelegy’s unique composition sets it apart in COPD management. Its triple therapy approach addresses bronchodilation, inflammation, and muscle relaxation. By combining different classes of medications, Trelegy aims to provide optimal symptom relief and improve patients’ ability to engage in daily activities. This comprehensive approach may result in increased exercise tolerance and a decreased need for rescue medications.

Breztri Vs Trelegy: Dosage and Administration

The dosing regimens for Breztri and Trelegy vary based on disease severity and individual patient factors. Healthcare providers tailor the treatment plan to meet each patient’s needs. Proper inhaler technique is crucial to ensure the medications reach the lungs effectively. Patients should receive thorough training on inhaler use and consult their healthcare provider if they have any difficulties.

Breztri Vs Trelegy: Cost Comparison

The cost of Breztri and Trelegy may differ depending on factors such as insurance coverage, location, and healthcare provider preferences. However, Trelegy is significantly cheaper with the price tag of around $12 per unit while for Breztri, the price tag goes as high as $65 per unit. Patients are encouraged to explore available options and discuss financial considerations with their healthcare team. In some cases, assistance programs or alternative medications may be available to help manage costs.

Breztri Vs Trelegy: Real-life Experiences

Real-life experiences of COPD patients who have used Breztri or Trelegy provide valuable insights into the medications’ effectiveness. These firsthand accounts can offer a glimpse into how the treatments impact daily life, symptom management, and overall well-being. Sharing experiences within COPD support groups or online communities can foster a sense of solidarity and shared knowledge.

Breztri Vs Trelegy: Efficacy Studies and Clinical Trials

Both Breztri and Trelegy have undergone extensive clinical trials to evaluate their safety and efficacy. These studies involve thousands of participants and assess various endpoints, including lung function improvement, symptom relief, and exacerbation reduction. The results of these trials provide healthcare providers with evidence-based guidance when recommending treatment options.

Side Effects: Breztri Vs Trelegy


Breztri, a combination inhaler that includes budesonide, glycopyrrolate, and formoterol fumarate, may lead to several common side effects. These can include:

  • Throat Irritation: Some individuals may experience throat discomfort or irritation after using Breztri. Rinsing the mouth after inhalation can help alleviate this symptom.
  • Coughing: Coughing may occur, particularly during the initial days of using Breztri. This is usually temporary and tends to subside with continued use.
  • Headache: Headaches can occur as the body adjusts to the medication. Staying hydrated and getting adequate rest may help reduce the frequency and intensity of headaches.
  • Infections: Corticosteroids like budesonide in Breztri can slightly increase the risk of respiratory infections. It’s important to monitor for any signs of infection and promptly seek medical attention if needed.


Trelegy, a triple therapy inhaler containing fluticasone furoate, umeclidinium, and vilanterol, may also lead to several common side effects. These can include:

  • Dry Mouth: Umeclidinium, an anticholinergic in Trelegy, can lead to dry mouth. Staying hydrated, chewing sugar-free gum, or using oral moisturizers may provide relief.
  • Throat Irritation: Similar to Breztri, Trelegy may cause throat irritation. Gargling with water after inhalation can help soothe the throat.
  • Hoarseness: Some individuals may experience hoarseness or changes in voice quality. This side effect is generally mild and transient.
  • Increased Heart Rate: Vilanterol, a long-acting beta-agonist in Trelegy, may cause an increase in heart rate. This effect is usually temporary and not a cause for concern unless severe.

Managing and Minimizing Side Effects

To manage and minimize side effects associated with Breztri and Trelegy:

  • Follow proper inhaler technique as demonstrated by your healthcare provider.
  • Stay well-hydrated and maintain good oral hygiene.
  • Report any persistent or severe side effects to your healthcare provider.

Breztri Vs Trelegy: Pros and Cons

Breztri and Trelegy are both triple combination inhalers designed to provide comprehensive COPD management. They contain different active ingredients and have unique mechanisms of action, leading to distinct pros and cons.



  • Comprehensive Action: Breztri’s combination of budesonide, glycopyrrolate, and formoterol fumarate addresses inflammation, bronchodilation, and muscle relaxation in one inhaler.
  • Symptom Control: Breztri’s comprehensive approach can lead to improved lung function, reduced exacerbations, and enhanced symptom control.
  • Single Inhaler Convenience: The three-in-one formulation reduces the need for multiple inhalers, promoting better adherence to the treatment regimen.


  • Side Effects: Breztri may lead to side effects such as throat irritation, coughing, and an increased risk of respiratory infections.
  • Limited Data: As a relatively newer medication, long-term data on Breztri’s effectiveness and safety may be limited.



  • Triple Therapy: Trelegy’s combination of fluticasone furoate, umeclidinium, and vilanterol provides comprehensive treatment targeting inflammation, bronchodilation, and muscle relaxation.
  • Quality of Life: Trelegy’s comprehensive action can improve lung function, exercise tolerance, and overall quality of life.
  • Long-Acting Benefits: Trelegy’s components provide long-lasting effects, reducing the need for frequent dosing.



  • Side Effects: Trelegy may lead to side effects like dry mouth, throat irritation, hoarseness, and an increased heart rate.
  • Cost Considerations: Trelegy’s cost may be a factor for some individuals, especially those without insurance coverage.

Choosing Between Breztri and Trelegy

The decision between Breztri and Trelegy should be a collaborative effort between patients and healthcare providers. Factors such as disease severity, medication preferences, potential interactions with other drugs, and individual response to treatment all play a role in the decision-making process. Open communication with your healthcare team ensures that the chosen medication aligns with your unique needs and goals.

Consulting Your Healthcare Provider

Before initiating or changing any COPD treatment, it’s crucial to consult your healthcare provider. They have the expertise to assess your condition, recommend suitable treatment options, and monitor your progress over time. Regular follow-up appointments allow for adjustments to the treatment plan based on your response and any changes in your health.

Managing COPD with Non-Pharmacological Approaches

In the realm of chronic obstructive pulmonary disease (COPD) management, a holistic approach extends beyond pharmacological interventions. Incorporating non-pharmacological strategies is essential for enhancing overall well-being, managing symptoms, and improving the quality of life for individuals living with COPD.

Lifestyle Modifications

Quit smoking, avoid pollutants, and create a COPD-friendly home environment. These simple yet impactful changes can alleviate symptoms and slow disease progression.

Breathing Techniques and Exercise

Learning proper breathing techniques and engaging in pulmonary rehabilitation exercises can improve lung function and increase tolerance to physical activities.

Diet and Emotional Well-Being

Maintain a balanced diet, stay hydrated, and seek emotional support to tackle anxiety and depression, which are common challenges for COPD patients.

Collaborate with Healthcare Providers

Close collaboration with healthcare providers ensures personalized guidance, regular monitoring, and adjustments to the treatment plan based on your evolving needs.


Breztri Vs Trelegy: Conclusion

Breztri and Trelegy represent significant advancements in COPD management, offering innovative combinations of medications to address the multifaceted nature of the disease. Their distinct formulations provide options for patients at various stages of COPD, enhancing symptom control and quality of life. The choice between these medications is highly individual and should be made in consultation with a healthcare provider who can provide personalized guidance and support. Other drugs should also be consulted to make an informed decision about the best treatment as per individual requirement.


Is TRELEGY the same as BREZTRI?

TRELEGY and BREZTRI are not exactly the same, but they are similar. Both are triple therapy inhalers used for COPD management. While TRELEGY contains fluticasone furoate, umeclidinium, and vilanterol, BREZTRI combines budesonide, glycopyrrolate, and formoterol fumarate. They share the goal of providing comprehensive treatment, but the specific combination of active ingredients sets them apart.

What is better than TRELEGY Ellipta?

Determining what is better than TRELEGY Ellipta depends on individual preferences and medical needs. While BREZTRI is another option with different active ingredients, consulting with a healthcare provider is essential for making an informed decision. Different individuals may respond differently to various medications, and the choice should be tailored to each person’s unique circumstances.

Which is better BREZTRI or Symbicort?

BREZTRI and Symbicort are both effective options for COPD management, but their specific advantages can vary. BREZTRI combines budesonide, glycopyrrolate, and formoterol fumarate, addressing inflammation, bronchodilation, and muscle relaxation. Symbicort contains budesonide and formoterol, targeting inflammation and bronchodilation. The choice between the two depends on factors like medical history, symptom severity, and individual response.

What is the number 1 inhaler for COPD?

There isn’t a single “number 1” inhaler for COPD that suits everyone. The choice of inhaler depends on factors such as disease severity, individual response, and personal preferences. Medications like BREZTRI, TRELEGY, Symbicort, and others offer effective COPD management options. A healthcare provider can guide you toward the most suitable inhaler based on your specific needs.

Why is BREZTRI so expensive?

The cost of medications, including BREZTRI, can be influenced by various factors, such as research and development expenses, manufacturing costs, and pricing strategies. Additionally, insurance coverage and geographic location can impact the final cost. Patients are encouraged to explore available assistance programs, discuss cost concerns with healthcare providers, and consider alternative options if necessary.

What inhaler is similar to BREZTRI?

TRELEGY is a similar inhaler to BREZTRI, as both are triple therapy inhalers for COPD. They differ in their combination of active ingredients. While BREZTRI contains budesonide, glycopyrrolate, and formoterol fumarate, TRELEGY combines fluticasone furoate, umeclidinium, and vilanterol. Consulting a healthcare provider is recommended to determine which inhaler is the best fit for an individual’s needs.

What are the top 5 inhalers for COPD?

The top inhalers for COPD include BREZTRI, TRELEGY, Symbicort, Anoro Ellipta, and Advair Diskus, among others. However, the “top” inhalers can vary depending on individual factors such as disease severity, medical history, and response to treatment. A healthcare provider can help identify the most suitable inhaler based on a patient’s specific condition.

Why is TRELEGY so expensive?

Similar to BREZTRI, the cost of TRELEGY can be influenced by factors such as research and development costs, manufacturing expenses, and pricing strategies. Insurance coverage and regional pricing variations can also contribute to the overall cost. Exploring financial assistance programs and discussing cost concerns with healthcare providers can help manage the expense of TRELEGY.

What medicine is equal to TRELEGY?

There is no exact medicine that is considered equal to TRELEGY, as each medication has its unique combination of active ingredients. However, BREZTRI is a comparable option, providing triple therapy for COPD with a different combination of budesonide, glycopyrrolate, and formoterol fumarate. Consultation with a healthcare provider is essential to determine the most appropriate alternative for an individual’s needs.

Does BREZTRI improve lung function?

Yes, BREZTRI has been shown to improve lung function in individuals with COPD. Its combination of budesonide, glycopyrrolate, and formoterol fumarate addresses inflammation, bronchodilation, and muscle relaxation, contributing to enhanced lung function and symptom control. However, individual responses may vary, and it’s important to follow the prescribed treatment plan and attend regular check-ups with a healthcare provider.

Is BREZTRI any good?

BREZTRI has demonstrated effectiveness in COPD management by addressing multiple aspects of the disease. Its triple therapy approach can lead to improved lung function, reduced exacerbations, and enhanced quality of life. However, the suitability of BREZTRI depends on individual factors, and consulting with a healthcare provider is essential to determine if it is a suitable option based on your specific condition.

Why is BREZTRI not recommended for asthma?

While BREZTRI is indicated for COPD management, it may not be recommended for asthma treatment. The specific combination of active ingredients in BREZTRI may not align with the therapeutic needs of individuals with asthma. Different medications and treatment approaches are typically used for asthma management. Consultation with a healthcare provider is crucial for determining the most appropriate treatment plan for asthma.

What is the newest treatment for COPD?

As of 2023, several new treatments for COPD have emerged. Among them are medications like revefenacin, which is a long-acting muscarinic antagonist (LAMA) bronchodilator. However, the newest treatment options can vary over time, and healthcare providers stay informed about the latest advancements to provide the most up-to-date recommendations for COPD management.

What is the newest medication for COPD?

In recent years, various new medications have been introduced for COPD. These include dual and triple therapy inhalers with novel combinations of active ingredients. Medications like budesonide/glycopyrrolate/formoterol fumarate (Breztri) and other emerging therapies aim to provide enhanced symptom control and improved lung function for individuals with COPD.

What is the new treatment for COPD in 2023?

As of 2023, the landscape of COPD treatment continues to evolve, with ongoing research and development efforts. Emerging treatments may include novel medications, improved inhaler technologies, and personalized approaches to disease management. Staying informed through discussions with healthcare providers and accessing reliable medical sources can provide insights into the latest advancements in COPD treatment.


  • National Heart, Lung, and Blood Institute. (2021). COPD: Chronic Obstructive Pulmonary Disease.
  • Global Initiative for Chronic Obstructive Lung Disease. (2022). Global Strategy for the Diagnosis, Management, and Prevention of COPD – 2022 Report.
  • Mayo Clinic. (2023). COPD: Symptoms & causes.
  • American Lung Association. (2023). COPD: Causes, Risk Factors, and Prevention.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Scroll to Top